Background: The discovery of Sodium-Glucose co-transporter-2 (SGLT2) inhibitors had
rewritten the treatment of diabetes mellitus with an impressive fall in the incidence of death and associated
Introduction: The SGLT2 inhibitors by inhibiting the SGLT2 in the proximal nephron, helps in reducing
the reabsorption of approximately 90% of the filtered glucose and increased urinary glucose excretion
Methods: The literature related to SGLT2 inhibitors has been thoroughly explored from various available
public domains and reviewed extensively for this article. Detailed and updated information
related to SGLT2 inhibitors with a major focus on the recently approved Ertuglifolzin is structured in
Result: The present review is an effort to understand the management of diabetes mellitus over the past
few decades with a special focus on the role of SGLT2 receptor in the causes of therapeutic and preventive
strategies for diabetes mellitus. Pragmatic placement of the currently available Canagliflozin,
Dapagliflozin, and Empagliflozin as oral antidiabetic agents has been done. Well accommodated stereochemistry
and a high docking score of Ertugliflozin in ligand-receptor simulation studies attribute to
its high potency.
Conclusion: This review highlights the unique mechanism of SGLT2 Inhibitors coupled with pleiotropic
benefits on weight and blood pressure, which make it an attractive choice of therapy to diabetic
patients, not controlled by other medications.